a 2017

CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER et. al.

Basic information

Original name

CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies

Authors

KOZLOVÁ, Veronika (203 Czech Republic, belonging to the institution), Aneta LEDEREROVÁ (203 Czech Republic, belonging to the institution), Viera VAKULOVÁ (703 Slovakia, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, belonging to the institution)

Edition

CEITEC PHD RETREAT II, Telč, 2017

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

10601 Cell biology

Confidentiality degree

is not subject to a state or trade secret

RIV identification code

RIV/00216224:14740/17:00106907

Organization unit

Central European Institute of Technology

Keywords in English

CD20; defect; cell
Changed: 17/5/2018 14:01, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies, CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies

Links

MUNI/A/1106/2016, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)
Investor: Masaryk University, Category A
NV15-33561A, research and development project
Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie